P3 Health Partners Inc. $PIII Shares Sold by Trinity Financial Advisors LLC

Key Points

• Trinity Financial Advisors LLC significantly reduced its investment in P3 Health Partners, selling 1,252,537 shares and lowering its position by 98%, leaving it with only 25,500 shares.
• Shares of P3 Health Partners opened at $8.60, with a market cap of $61.83 million and a negative earnings report indicating an EPS of ($6.23), missing analysts' expectations.
• Analysts from Lake Street Capital have initiated coverage on P3 Health Partners with a "buy" rating and a target price of $20.00, reflecting moderate outlook for the stock.

Trinity Financial Advisors LLC lowered its position in P3 Health Partners Inc. (NASDAQ:PIII - Free Report) by 98.0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 25,500 shares of the company's stock after selling 1,252,537 shares during the quarter. Trinity Financial Advisors LLC owned 0.35% of P3 Health Partners worth $161,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in PIII. Cresset Asset Management LLC lifted its holdings in P3 Health Partners by 33.3% in the 1st quarter. Cresset Asset Management LLC now owns 200,000 shares of the company's stock worth $33,000 after buying an additional 50,000 shares in the last quarter. Abundance Wealth Counselors increased its position in shares of P3 Health Partners by 77.3% in the 1st quarter. Abundance Wealth Counselors now owns 400,000 shares of the company's stock worth $66,000 after purchasing an additional 174,395 shares during the last quarter. Finally, Wealthedge Investment Advisors LLC bought a new stake in shares of P3 Health Partners in the 4th quarter worth about $83,000. Institutional investors and hedge funds own 7.75% of the company's stock.

Wall Street Analysts Forecast Growth

Separately, Lake Street Capital began coverage on shares of P3 Health Partners in a research report on Thursday, August 28th. They issued a "buy" rating and a $20.00 target price for the company. One research analyst has rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $16.25.

P3 Health Partners Price Performance

Shares of NASDAQ:PIII opened at $8.60 on Friday. The company has a quick ratio of 0.31, a current ratio of 0.31 and a debt-to-equity ratio of 2.29. The firm has a 50-day simple moving average of $7.30 and a 200 day simple moving average of $7.79. The company has a market cap of $61.83 million, a PE ratio of -0.19 and a beta of 0.82. P3 Health Partners Inc. has a fifty-two week low of $5.80 and a fifty-two week high of $26.99.

P3 Health Partners (NASDAQ:PIII - Get Free Report) last posted its earnings results on Thursday, August 14th. The company reported ($6.23) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($3.29) by ($2.94). The firm had revenue of $355.79 million for the quarter, compared to analyst estimates of $356.52 million. P3 Health Partners had a negative net margin of 9.99% and a negative return on equity of 183.60%. P3 Health Partners has set its FY 2025 guidance at EPS. On average, sell-side analysts anticipate that P3 Health Partners Inc. will post -0.67 EPS for the current year.

About P3 Health Partners

P3 Health Partners Inc, a patient-centered and physician-led population health management company, provides superior care services in the United States. It operates clinics and wellness centers. P3 Health Partners Inc was founded in 2020 and is based in Henderson, Nevada.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.